Yousif Capital Management LLC Lowers Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Yousif Capital Management LLC decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 27,027 shares of the specialty pharmaceutical company’s stock after selling 374 shares during the period. Yousif Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,324,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $611,000. Exchange Traded Concepts LLC increased its position in Jazz Pharmaceuticals by 6.6% during the 3rd quarter. Exchange Traded Concepts LLC now owns 4,604 shares of the specialty pharmaceutical company’s stock valued at $596,000 after purchasing an additional 284 shares during the period. Asset Management One Co. Ltd. raised its holdings in shares of Jazz Pharmaceuticals by 12.0% in the 3rd quarter. Asset Management One Co. Ltd. now owns 28,124 shares of the specialty pharmaceutical company’s stock valued at $3,640,000 after purchasing an additional 3,004 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Jazz Pharmaceuticals by 10.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company’s stock worth $1,304,000 after purchasing an additional 962 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Jazz Pharmaceuticals by 6.3% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 35,647 shares of the specialty pharmaceutical company’s stock valued at $4,614,000 after purchasing an additional 2,100 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 1.9 %

JAZZ stock opened at $109.46 on Monday. Jazz Pharmaceuticals plc has a 12-month low of $106.61 and a 12-month high of $146.70. The business’s 50-day moving average is $118.25 and its 200 day moving average is $121.69. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The stock has a market cap of $6.90 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 1.51 and a beta of 0.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on JAZZ shares. UBS Group reduced their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, March 1st. Truist Financial reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Barclays reduced their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $220.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.